A large study found that expanded Medicaid coverage under the Affordable Care Act leads to better survival outcomes for young adults ages 18-39 newly diagnosed with cancer, particularly those who identified as Hispanic or non-Hispanic Black.
The Cancer History Project preserves legacies, stories, and transcripts.
The Max Foundation, a global nonprofit organization that aims to accelerate health equity by delivering medication, technology, and supportive services to patients globally, will launch access to the Novartis therapy Scemblix (asciminib) in 36 low- and middle-income countries in 2023 for people living with chronic myeloid leukemia as part of the CancerPath to Care collaboration with Novartis.
UPMC Hillman Cancer Center named Charles Edward Geyer, Jr., Monica L. Baskin, and Kathryn H. Schmitz to leadership positions.
Terry Hyslop was named co-leader of the Cancer Risk and Control Program at Jefferson Health’s Sidney Kimmel Cancer Center named.
As Ben Ho Park sees it, the mission of a cancer researcher doesn’t stop at the water’s edge. It follows that Park’s new role as director of Vanderbilt-Ingram Cancer Center is inseparable from his role as an executive of the Global Cancer Institute, a nonprofit that works with healthcare providers in low- and middle-income countries to improve survival rates for underserved cancer patients.
Up to 15% of U.S. counties—home to about 25 million Americans—fall outside the reach of the catchment area of this country’s cancer centers.
Drawing on Charles Dickens, NCI Acting Director Douglas Lowy has a teaching moment for oncology: we live in the best of times as well as the worst of times, because only fragments of human society—both in the United States and in low- and middle-income countries—fully benefit from modern cancer care.
Discovery of new cancer treatments and detection tools makes it all the more urgent to address health disparities, the American Association for Cancer Research 2022 Cancer Progress Report said.
Moffitt Cancer Center has conducted the first prospective study to investigate genomic biomarkers associated with aggressive disease in African American men with prostate cancer, a population with disparities in incidence and mortality.
